Pharsight

1. List of Rinvoq drug patents

Application	Filing Date	Opposition Party	Legal Status
EP10835061A	2018-02-16	Generics (U.K.) Limited	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221	ABBVIE INC	Tricyclic compounds	Dec, 2030 (7 years from now)
US8962629	ABBVIE INC	Tricyclic compounds	Jan, 2031 (7 years from now)
US11186584	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10981923	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US9951080	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9963459	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof	Oct, 2036 (13 years from now)
US10550126	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10995095	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10597400	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10519164	ABBVIE INC	Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11198697	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10730883	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10344036	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11365198	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10202393	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11512092	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10981924	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)

Do you want to check out RINVOQ patents from before 2022?

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 14, 2024
New Chemical Entity Exclusivity (NCE)	Aug 16, 2024

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products,...

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
45MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

RINVOQ family patents

United States

Singapore

Japan

China

Australia

Canada

European Union

Korea, Republic of

Israel

Taiwan

Russia

Dominican Republic

Brazil

Hong Kong

Ukraine

Argentina

New Zealand

Peru

Mexico

Costa Rica

Hungary

Uruguay

Spain

Malaysia

Denmark

Poland

Norway

Croatia

Cyprus

Chile

Portugal

Ecuador

South Africa

Colombia

Lithuania

Slovenia

Philippines

Netherlands

Luxembourg

2. List of Rinvoq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11524964	ABBVIE	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11535624	ABBVIE	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11535625	ABBVIE	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11535626	ABBVIE	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11607411	ABBVIE	Methods of treating Crohn's disease and ulcerative colitis	Mar, 2038 (14 years from now)

Do you want to check out RINVOQ patents from before 2022?

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 14, 2024
New Chemical Entity Exclusivity (NCE)	Aug 16, 2024

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with moderately to severely active rheumatoid...

Dosage: TABLET, EXTENDED RELEASE;ORAL